help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castro, M. R.
Right arrow Articles by Morris, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castro, M. R.
Right arrow Articles by Morris, J. C.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 8 2957-2962
Copyright © 1999 by The Endocrine Society

Original Studies

Development of Monoclonal Antibodies Against the Human Sodium Iodide Symporter: Immunohistochemical Characterization of This Protein in Thyroid Cells1

M. Regina Castro, Elizabeth R. Bergert, Thomas G. Beito, Bryan McIver, John R. Goellner and John C. Morris

Division of Endocrinology & Metabolism (M.R.C., E.R.B., B.M., J.C.M.), Immunology (T.G.B.) and Pathology (J.R.G.). Mayo Clinic and Mayo Graduate Medical School, Rochester, Minnesota 55905

Address correspondence and requests for reprints to: John C. Morris, MD Mayo Clinic, Division of Endocrinology, 200 First Street SW, Rochester, Minnesota 55905. E-mail: Morris.John{at}Mayo.edu

The thyroid sodium-iodide symporter (NIS) is responsible for iodide concentrating ability within thyroid follicular cells. We sought to develop monoclonal antibodies against human NIS (hNIS) for use as reagents in structure-function studies of the protein, as well as potential tools in the assessment of NIS expression in benign and malignant thyroid tissues. Synthetic peptides corresponding to the second ExMD and to the carboxy-terminal ExMD of hNIS were produced and utilized as antigens to develop monoclonal antibodies, which were tested by Western blotting using membranes prepared from COS-7 cells transiently transfected with a pcDNA3 plasmid containing the gene for the full-length hNIS, or a control vector. Western blotting showed a major band with molecular weight (MW) of approximately 97 kDa and several minor bands with MW of approximately 160 kDa, 68 kDa, 30 kDa, and 15 kDa, all specific for hNIS-transfected cells. Immunohistochemistry was performed in various types of thyroid tissues and nonthyroidal tissues, using the monoclonal antibodies. Strong immunostaining was observed in Graves’ tissue, intermediate staining in papillary and follicular thyroid cancer, and no staining in Hürthle cell cancer or in nonthyroidal tissue. The staining was specific for the follicular epithelium in each of the tissues and was most intense in the basolateral portion of the cell membrane. Overall, our observations indicate that the monoclonal antibodies are specific for hNIS and will be invaluable reagents for investigating the role of NIS in thyroid disease.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. K. M. B. Sodre, I. G. S. Rubio, A. L. R. Galrao, M. Knobel, E. K. Tomimori, V. A. F. Alves, C. T. Kanamura, C. A. Buchpiguel, T. Watanabe, C. U. M. Friguglietti, et al.
Association of Low Sodium-Iodide Symporter Messenger Ribonucleic Acid Expression in Malignant Thyroid Nodules with Increased Intracellular Protein Staining
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4141 - 4145.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. J. Yeom, J.-K. Chung, J. H. Kang, Y. H. Jeon, K. I. Kim, Y. N. Jin, Y. M. Lee, J. M. Jeong, and D. S. Lee
Visualization of Hypoxia-Inducible Factor-1 Transcriptional Activation in C6 Glioma Using Luciferase and Sodium Iodide Symporter Genes
J. Nucl. Med., September 1, 2008; 49(9): 1489 - 1497.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Kogai, K Taki, and G A Brent
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
H.-Y. Lin, L. Lansing, J.-M. Merillon, F. B. Davis, H.-Y. Tang, A. Shih, X. Vitrac, S. Krisa, T. Keating, H. J. Cao, et al.
Integrin {alpha}V{beta}3 contains a receptor site for resveratrol
FASEB J, August 1, 2006; 20(10): 1742 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris
In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter
Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
M. A Fragoso, V. Fernandez, R. Forteza, S. H Randell, M. Salathe, and G. E Conner
Transcellular thiocyanate transport by human airway epithelia
J. Physiol., November 15, 2004; 561(1): 183 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Trouttet-Masson, S. Selmi-Ruby, F. Bernier-Valentin, V. Porra, N. Berger-Dutrieux, M. Decaussin, J.-L. Peix, A. Perrin, C. Bournaud, J. Orgiazzi, et al.
Evidence for Transcriptional and Posttranscriptional Alterations of the Sodium/Iodide Symporter Expression in Hypofunctioning Benign and Malignant Thyroid Tumors
Am. J. Pathol., July 1, 2004; 165(1): 25 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kakinuma, E. R. Bergert, C. Spitzweg, J. C. Cheville, M. M. Lieber, and J. C. Morris
Probasin Promoter (ARR2PB)-Driven, Prostate-Specific Expression of the Human Sodium Iodide Symporter (h-NIS) for Targeted Radioiodine Therapy of Prostate Cancer
Cancer Res., November 15, 2003; 63(22): 7840 - 7844.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Schipper, A. Weber, M. Behe, R. Goke, W. Joba, H. Schmidt, T. Bert, B. Simon, R. Arnold, A. E. Heufelder, et al.
Radioiodide Treatment after Sodium Iodide Symporter Gene Transfer Is a Highly Effective Therapy in Neuroendocrine Tumor Cells
Cancer Res., March 15, 2003; 63(6): 1333 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
T. Kondo, N. Nakamura, K. Suzuki, S.-i. Murata, A. Muramatsu, A. Kawaoi, and R. Katoh
Expression of Human Pendrin in Diseased Thyroids
J. Histochem. Cytochem., February 1, 2003; 51(2): 167 - 173.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Castro, E. R. Bergert, J. R. Goellner, I. D. Hay, and J. C. Morris
Immunohistochemical Analysis of Sodium Iodide Symporter Expression in Metastatic Differentiated Thyroid Cancer: Correlation with Radioiodine Uptake
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5627 - 5632.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Spitzweg, K. J. Harrington, L. A. Pinke, R. G. Vile, and J. C. Morris
The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3327 - 3335.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society